首页 > 最新文献

Value in health regional issues最新文献

英文 中文
Adapting a Benefit Trade-Off Instrument to Measure Health Inequality Aversion in the United States 采用利益权衡工具来衡量美国人对健康不平等的厌恶
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-12-12 DOI: 10.1016/j.vhri.2025.101556
Salome Ricci PharmD, MS , Stacey Kowal MSc , Susan dosReis PhD , Julia F. Slejko PhD

Objectives

Health equity is increasingly central to healthcare decision making, necessitating robust methods to incorporate equity considerations into health technology assessment. The benefit trade-off (BTO) approach measures health inequality aversion—how much total population health individuals would sacrifice to reduce health inequalities. However, these complex preference measurement tools need to be adapted and contextualized for use in different country settings. In this work, we aimed to adapt a BTO instrument, originally developed in the United Kingdom, to measure health inequality aversion in the United States general population.

Methods

We modified the BTO instrument through an iterative process that addressed US-specific contextual elements and technical comprehension requirements. We conducted 3 rounds of pretesting (n = 11) followed by pilot testing (n = 150) to optimize the instrument. The final BTO was implemented in an online survey completed by 2064 participants, recruited through a Qualtrics panel, with demographic quotas aligned to US Census data.

Results

Adaptation to enhance technical and conceptual comprehension included the development of localized instructional videos and implementation of new comprehension checks. Among complete responses, 63% provided valid responses suitable for inequality aversion parameter analysis, up from 33% in the initial pilot. The final sample was representative of US adults, although with higher age and educational attainment.

Conclusions

Our adaptation used a structured approach, similar to other ongoing studies, for measuring societal health inequality preferences. By achieving valid response rates in line with the original UK study, our US study adds to the evidence base for best practice guidance, informing future adaptations across different country settings.
卫生公平在卫生保健决策中越来越重要,因此需要强有力的方法将公平考虑纳入卫生技术评估。利益权衡(BTO)方法衡量的是对健康不平等的厌恶程度——为了减少健康不平等,总健康个体会牺牲多少。然而,这些复杂的偏好测量工具需要进行调整,并根据不同国家的情况加以使用。在这项工作中,我们的目标是采用最初在英国开发的BTO工具来衡量美国普通人群对健康不平等的厌恶。方法:我们通过一个迭代过程修改了BTO仪器,以解决美国特定的上下文元素和技术理解要求。我们进行了3轮预试(n = 11)和中试(n = 150)来优化仪器。最终的BTO是在一项由2064名参与者完成的在线调查中实施的,这些参与者是通过qualics小组招募的,人口配额与美国人口普查数据一致。结果提高技术和概念理解的适应措施包括开发本地化教学视频和实施新的理解测试。在完整的回答中,63%的人提供了适合不平等厌恶参数分析的有效回答,高于初始试点的33%。最后一个样本是具有代表性的美国成年人,尽管他们的年龄和受教育程度更高。与其他正在进行的研究类似,我们采用结构化方法来衡量社会健康不平等偏好。通过实现与英国原始研究一致的有效回复率,我们的美国研究增加了最佳实践指导的证据基础,为未来在不同国家环境下的适应提供了信息。
{"title":"Adapting a Benefit Trade-Off Instrument to Measure Health Inequality Aversion in the United States","authors":"Salome Ricci PharmD, MS ,&nbsp;Stacey Kowal MSc ,&nbsp;Susan dosReis PhD ,&nbsp;Julia F. Slejko PhD","doi":"10.1016/j.vhri.2025.101556","DOIUrl":"10.1016/j.vhri.2025.101556","url":null,"abstract":"<div><h3>Objectives</h3><div>Health equity is increasingly central to healthcare decision making, necessitating robust methods to incorporate equity considerations into health technology assessment. The benefit trade-off (BTO) approach measures health inequality aversion—how much total population health individuals would sacrifice to reduce health inequalities. However, these complex preference measurement tools need to be adapted and contextualized for use in different country settings. In this work, we aimed to adapt a BTO instrument, originally developed in the United Kingdom, to measure health inequality aversion in the United States general population.</div></div><div><h3>Methods</h3><div>We modified the BTO instrument through an iterative process that addressed US-specific contextual elements and technical comprehension requirements. We conducted 3 rounds of pretesting (<em>n</em> = 11) followed by pilot testing (<em>n</em> = 150) to optimize the instrument. The final BTO was implemented in an online survey completed by 2064 participants, recruited through a Qualtrics panel, with demographic quotas aligned to US Census data.</div></div><div><h3>Results</h3><div>Adaptation to enhance technical and conceptual comprehension included the development of localized instructional videos and implementation of new comprehension checks. Among complete responses, 63% provided valid responses suitable for inequality aversion parameter analysis, up from 33% in the initial pilot. The final sample was representative of US adults, although with higher age and educational attainment.</div></div><div><h3>Conclusions</h3><div>Our adaptation used a structured approach, similar to other ongoing studies, for measuring societal health inequality preferences. By achieving valid response rates in line with the original UK study, our US study adds to the evidence base for best practice guidance, informing future adaptations across different country settings.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"51 ","pages":"Article 101556"},"PeriodicalIF":1.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145747177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Analysis of Adherence to Antimicrobial Guidelines as Part of Antimicrobial Stewardship Strategies in 6 Latin American Countries: A Pilot Experience Focusing on Economic Impact 6个拉丁美洲国家遵守抗微生物药物指南作为抗微生物药物管理战略一部分的成本分析:侧重于经济影响的试点经验
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-12-12 DOI: 10.1016/j.vhri.2025.101550
Natalia Restrepo-Arbeláez MD, MPH , Elkin V. Lemos-Luengas MD, PhD , Juan Carlos García-Betancur PhD , Wanda Cornistein MD , Diogo Boldim-Ferreira MD , Rodrigo Ahumada MD , Jorge Chaverri-Murillo MD , Paulo Castañeda-Méndez MD , Luis Hercilla MD , María Virginia Villegas MD, MSc

Objectives

This study presents a pilot cost analysis and case-study comparison of adherence to antimicrobial stewardship (AMS) guidelines across 6 high-complexity healthcare institutions in Latin America and the Caribbean. It aims to evaluate the economic impact of adhering to these guidelines in hospitals implementing step-by-step processes to establish AMS programs within their institutions.

Methods

A multicenter, retrospective, observational study was conducted in Argentina, Brazil, Chile, Costa Rica, United Mexican States, and Peru. A standardized Cost Report Form collected data on 2 comparable patients per institution, 1 treated according to AMS guidelines and 1 without adherence. Data included hospitalization days, intensive care unit costs, antibiotic use, and total management expenses, converted to US dollars. A sensitivity analysis varied key cost parameters (hospitalization, intensive care unit stays, and antibiotics) by ±20% to assess cost stability.

Results

Adherence to AMS guidelines led to hospitalization net cost reductions across all institutions: Peru (57.8%), Argentina (49.6%), United Mexican States (38.9%), Brazil (2.6%), Chile (10.2%), and Costa Rica (7.6%). Daily cost savings per patient ranged from US dollars $3 (Brazil) to $570 (Peru). Sensitivity analysis confirmed stability under varying conditions, with adjusted savings from $810 to $9.999.

Conclusions

This case-study highlights the economic benefits of AMS adherence, including reduced hospitalization and antibiotic costs. Findings provide insights supporting AMS program expansion across Latin America and the Caribbean healthcare systems to optimize resources.
目的:本研究对拉丁美洲和加勒比地区6家高复杂性医疗机构抗菌剂管理(AMS)指南的遵守情况进行了试点成本分析和案例研究比较。它的目的是评估遵守这些指导方针的经济影响,在医院实施逐步的过程,在他们的机构内建立辅助医疗系统。方法在阿根廷、巴西、智利、哥斯达黎加、墨西哥合众国和秘鲁进行了一项多中心回顾性观察研究。一份标准化的成本报告表收集了每家机构2名可比较患者的数据,1名患者按照AMS指南治疗,1名患者没有依从治疗。数据包括住院天数、重症监护病房费用、抗生素使用和折合成美元的总管理费用。敏感性分析将关键成本参数(住院、重症监护病房和抗生素)变化±20%,以评估成本稳定性。结果:秘鲁(57.8%)、阿根廷(49.6%)、美国(38.9%)、巴西(2.6%)、智利(10.2%)和哥斯达黎加(7.6%)等所有机构的住院净成本均因遵循AMS指南而降低。每位患者每天节省的费用从3美元(巴西)到570美元(秘鲁)不等。敏感性分析证实了在不同条件下的稳定性,调整后的节省从810美元到9.999美元。本案例研究强调了AMS依从性的经济效益,包括减少住院和抗生素费用。研究结果为支持AMS项目在拉丁美洲和加勒比地区医疗保健系统的扩展提供了见解,以优化资源。
{"title":"Cost-Analysis of Adherence to Antimicrobial Guidelines as Part of Antimicrobial Stewardship Strategies in 6 Latin American Countries: A Pilot Experience Focusing on Economic Impact","authors":"Natalia Restrepo-Arbeláez MD, MPH ,&nbsp;Elkin V. Lemos-Luengas MD, PhD ,&nbsp;Juan Carlos García-Betancur PhD ,&nbsp;Wanda Cornistein MD ,&nbsp;Diogo Boldim-Ferreira MD ,&nbsp;Rodrigo Ahumada MD ,&nbsp;Jorge Chaverri-Murillo MD ,&nbsp;Paulo Castañeda-Méndez MD ,&nbsp;Luis Hercilla MD ,&nbsp;María Virginia Villegas MD, MSc","doi":"10.1016/j.vhri.2025.101550","DOIUrl":"10.1016/j.vhri.2025.101550","url":null,"abstract":"<div><h3>Objectives</h3><div>This study presents a pilot cost analysis and case-study comparison of adherence to antimicrobial stewardship (AMS) guidelines across 6 high-complexity healthcare institutions in Latin America and the Caribbean. It aims to evaluate the economic impact of adhering to these guidelines in hospitals implementing step-by-step processes to establish AMS programs within their institutions.</div></div><div><h3>Methods</h3><div>A multicenter, retrospective, observational study was conducted in Argentina, Brazil, Chile, Costa Rica, United Mexican States, and Peru. A standardized Cost Report Form collected data on 2 comparable patients per institution, 1 treated according to AMS guidelines and 1 without adherence. Data included hospitalization days, intensive care unit costs, antibiotic use, and total management expenses, converted to US dollars. A sensitivity analysis varied key cost parameters (hospitalization, intensive care unit stays, and antibiotics) by ±20% to assess cost stability.</div></div><div><h3>Results</h3><div>Adherence to AMS guidelines led to hospitalization net cost reductions across all institutions: Peru (57.8%), Argentina (49.6%), United Mexican States (38.9%), Brazil (2.6%), Chile (10.2%), and Costa Rica (7.6%). Daily cost savings per patient ranged from US dollars $3 (Brazil) to $570 (Peru). Sensitivity analysis confirmed stability under varying conditions, with adjusted savings from $810 to $9.999.</div></div><div><h3>Conclusions</h3><div>This case-study highlights the economic benefits of AMS adherence, including reduced hospitalization and antibiotic costs. Findings provide insights supporting AMS program expansion across Latin America and the Caribbean healthcare systems to optimize resources.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"51 ","pages":"Article 101550"},"PeriodicalIF":1.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145747181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scaling-Up Nutrition: A Benefit-Cost and Cost-Effectiveness Analysis of Increasing Coverage of Nutrition Interventions in the Republic of Yemen 扩大营养:也门共和国扩大营养干预覆盖面的效益-成本和成本效益分析
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-12-12 DOI: 10.1016/j.vhri.2025.101560
Lubina F. Qureshy PhD , Mohini Kak MSc , Katriel Friedman MPA/ID , Kent David Garber MD , Priyanka Kanth MA , Sherin Varkey MD

Objectives

This article presents a benefit-cost analysis of scaling-up a subset of nutrition interventions administered in the Republic of Yemen with moderate to strong evidence of impact over 2024 to 2030. It also undertakes a cost-effectiveness analysis of adding interventions that are a part of the currently implemented nutrition package but with a weak evidence base.

Methods

We value economic benefits by converting the change in outcome expected from each intervention into a monetary value, in terms of savings from illness costs and future earnings from productivity and cognitive gains, discounted to its present value. To compare cost-effectiveness across packages, we calculate gain in disability-adjusted life-years as equivalent to the incremental improvement in outcomes from the additional coverage.

Results

The benefit-cost ratio for the scale-up is 2.23. The ratio remains above 1 with stricter assumptions. The incremental cost-effectiveness ratio of scaling up with the 2 additional investments is US$1337/disability-adjusted life-year for the 7-year period and is the equivalent of 0.6 times the current gross domestic product per capita, within a recommended cost-effectiveness threshold.

Conclusions

Because the additional cost of scaling up a comprehensive package is 40% of what the scale-up of the core package would cost for the period, it will need careful consideration of whether the scale-up for additional interventions with weak evidence in support of their effectiveness is warranted, even if the incremental cost-effectiveness ratio meets the threshold requirement.
本文对也门共和国实施的一系列营养干预措施进行了效益-成本分析,并有中度至强烈的证据表明其在2024年至2030年期间会产生影响。它还对增加作为目前实施的营养一揽子计划一部分但证据基础薄弱的干预措施进行了成本效益分析。方法我们通过将每次干预预期结果的变化转换为货币价值来评估经济效益,以疾病成本的节省和生产力和认知收益的未来收益为基础,贴现为其现值。为了比较不同方案的成本效益,我们计算残疾调整生命年的收益,将其等同于额外覆盖带来的结果的增量改善。结果扩大规模的效益成本比为2.23。在更严格的假设下,这一比率仍高于1。在建议的成本效益阈值范围内,增加两项投资的增量成本效益比为7年期间每残疾调整生命年1337美元,相当于目前人均国内生产总值的0.6倍。由于扩大综合一揽子措施的额外成本是该时期扩大核心一揽子措施所需成本的40%,因此需要仔细考虑,即使增量成本-效果比达到阈值要求,是否有必要扩大证据不足的额外干预措施的有效性。
{"title":"Scaling-Up Nutrition: A Benefit-Cost and Cost-Effectiveness Analysis of Increasing Coverage of Nutrition Interventions in the Republic of Yemen","authors":"Lubina F. Qureshy PhD ,&nbsp;Mohini Kak MSc ,&nbsp;Katriel Friedman MPA/ID ,&nbsp;Kent David Garber MD ,&nbsp;Priyanka Kanth MA ,&nbsp;Sherin Varkey MD","doi":"10.1016/j.vhri.2025.101560","DOIUrl":"10.1016/j.vhri.2025.101560","url":null,"abstract":"<div><h3>Objectives</h3><div>This article presents a benefit-cost analysis of scaling-up a subset of nutrition interventions administered in the Republic of Yemen with moderate to strong evidence of impact over 2024 to 2030. It also undertakes a cost-effectiveness analysis of adding interventions that are a part of the currently implemented nutrition package but with a weak evidence base.</div></div><div><h3>Methods</h3><div>We value economic benefits by converting the change in outcome expected from each intervention into a monetary value, in terms of savings from illness costs and future earnings from productivity and cognitive gains, discounted to its present value. To compare cost-effectiveness across packages, we calculate gain in disability-adjusted life-years as equivalent to the incremental improvement in outcomes from the additional coverage.</div></div><div><h3>Results</h3><div>The benefit-cost ratio for the scale-up is 2.23. The ratio remains above 1 with stricter assumptions. The incremental cost-effectiveness ratio of scaling up with the 2 additional investments is US$1337/disability-adjusted life-year for the 7-year period and is the equivalent of 0.6 times the current gross domestic product per capita, within a recommended cost-effectiveness threshold.</div></div><div><h3>Conclusions</h3><div>Because the additional cost of scaling up a comprehensive package is 40% of what the scale-up of the core package would cost for the period, it will need careful consideration of whether the scale-up for additional interventions with weak evidence in support of their effectiveness is warranted, even if the incremental cost-effectiveness ratio meets the threshold requirement.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"52 ","pages":"Article 101560"},"PeriodicalIF":1.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impoverishment Effect of Out-of-Pocket Expenditure for Hypertension in Ghana 自费高血压治疗在加纳的贫困效应
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-12-11 DOI: 10.1016/j.vhri.2025.101557
Kofi Aduo-Adjei MPhil , Øystein Ariansen Haaland PhD , Lumbwe Chola PhD , James Akazili PhD

Objectives

The rising prevalence of hypertension in Ghana and the associated household expenditures have become major policy concerns. High out-of-pocket (OOP) payments restrict access to care and increase the risk of impoverishment. This study examines the level and effect of household impoverishment due to care-seeking for hypertension in Ghana.

Methods

We analyzed data from a catastrophic health expenditure survey conducted between December 2023 and February 2024 at 2 primary healthcare facilities: Weija Gbawe Municipal Hospital (WGMH) and Shai Osudoku District Hospital (SODH) in the Greater Accra Region. The analysis involved descriptive statistics and estimation of the impact of OOP payment on impoverishment, including a pen’s parade of household per capita expenditure.

Results

The findings show that OOP led to an increase in the poverty headcount by 3.14% and 0.26% using US dollars $2.15/per day and $3.65/per day, respectively. At a lower threshold, the household poverty gap increased from $40.10 to $46.57 and widened from $83.86 to $90.79. The normalized poverty gap grew from 62.17% to 72.20% at a lower poverty line and from 76.58% to 82.92% at the higher threshold. It also emerged that the normalized mean poverty also increased from 61.78% to 69.62% at a poverty threshold of $2.15 and from 129.8% to 141.92% at $3.65 of the poverty line.

Conclusions

Our findings suggest that without financial risk protection, households are likely to be pushed into extreme poverty because of expenditures on hypertension care. Urgent intervention is needed to mitigate the impoverishing effects of noncommunicable diseases in Ghana.
加纳高血压患病率的上升和相关的家庭支出已成为主要的政策关注点。高额的自付费用限制了获得医疗服务的机会,增加了贫困的风险。本研究考察了加纳因高血压求诊而导致的家庭贫困水平和影响。方法分析了2023年12月至2024年2月在大阿克拉地区Weija Gbawe市医院(WGMH)和Shai Osudoku区医院(SODH)两家初级卫生保健机构进行的灾难性卫生支出调查数据。这项分析涉及描述性统计和估计OOP付款对贫困的影响,包括对家庭人均支出的大笔统计。结果研究结果表明,以2.15美元/天和3.65美元/天为标准,面向对象计划使贫困人口分别增加了3.14%和0.26%。在较低的门槛下,家庭贫困差距从40.10美元扩大到46.57美元,从83.86美元扩大到90.79美元。贫困线较低时,标准化贫困差距从62.17%扩大到72.20%;贫困线较高时,标准化贫困差距从76.58%扩大到82.92%。在2.15美元的贫困线上,标准化平均贫困率也从61.78%上升到69.62%,在3.65美元的贫困线上,标准化平均贫困率从129.8%上升到141.92%。结论研究结果表明,如果没有财务风险保护,家庭很可能因高血压护理支出而陷入极端贫困。需要采取紧急干预措施,以减轻非传染性疾病在加纳造成的贫困影响。
{"title":"The Impoverishment Effect of Out-of-Pocket Expenditure for Hypertension in Ghana","authors":"Kofi Aduo-Adjei MPhil ,&nbsp;Øystein Ariansen Haaland PhD ,&nbsp;Lumbwe Chola PhD ,&nbsp;James Akazili PhD","doi":"10.1016/j.vhri.2025.101557","DOIUrl":"10.1016/j.vhri.2025.101557","url":null,"abstract":"<div><h3>Objectives</h3><div>The rising prevalence of hypertension in Ghana and the associated household expenditures have become major policy concerns. High out-of-pocket (OOP) payments restrict access to care and increase the risk of impoverishment. This study examines the level and effect of household impoverishment due to care-seeking for hypertension in Ghana.</div></div><div><h3>Methods</h3><div>We analyzed data from a catastrophic health expenditure survey conducted between December 2023 and February 2024 at 2 primary healthcare facilities: Weija Gbawe Municipal Hospital (WGMH) and Shai Osudoku District Hospital (SODH) in the Greater Accra Region. The analysis involved descriptive statistics and estimation of the impact of OOP payment on impoverishment, including a pen’s parade of household per capita expenditure.</div></div><div><h3>Results</h3><div>The findings show that OOP led to an increase in the poverty headcount by 3.14% and 0.26% using US dollars $2.15/per day and $3.65/per day, respectively. At a lower threshold, the household poverty gap increased from $40.10 to $46.57 and widened from $83.86 to $90.79. The normalized poverty gap grew from 62.17% to 72.20% at a lower poverty line and from 76.58% to 82.92% at the higher threshold. It also emerged that the normalized mean poverty also increased from 61.78% to 69.62% at a poverty threshold of $2.15 and from 129.8% to 141.92% at $3.65 of the poverty line.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that without financial risk protection, households are likely to be pushed into extreme poverty because of expenditures on hypertension care. Urgent intervention is needed to mitigate the impoverishing effects of noncommunicable diseases in Ghana.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"54 ","pages":"Article 101557"},"PeriodicalIF":1.5,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Colorectal Cancer With High Microsatellite Instability or Mismatched Repair Deficiency in Japan 派姆单抗作为一线治疗日本晚期结直肠癌高微卫星不稳定性或错配修复缺陷的成本效益
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-12-10 DOI: 10.1016/j.vhri.2025.101555
Seiya Taniguchi BS , Kensuke Moriwaki MS, PhD , Kosuke Morimoto MS , Kojiro Shimozuma MD, PhD

Objectives

This study aimed to evaluate the cost-effectiveness of pembrolizumab (PEM) for treating patients with advanced colorectal cancer with high microsatellite instability or mismatched repair deficiency in Japan.

Methods

A partitioned survival analysis model was developed to predict costs and quality-adjusted life-years (QALYs) in PEM and standard-of-care (SoC) groups. Survival data for model extrapolation were obtained from the KEYNOTE-177 trial. Drug costs were based on official Japanese pricing, and other medical costs were estimated using a claims database provided by a health insurance association. A 2% discount rate was applied. Utility values were derived from previously published studies. The incremental cost-effectiveness ratio (ICER) of PEM compared with SoC was calculated and evaluated against Japan’s willingness-to-pay threshold. Sensitivity analyses were conducted to assess parameter uncertainty.

Results

The incremental cost of PEM compared with SoC was estimated at JPY15 554 008 with an incremental gain of 2.47 QALYs. Based on these results, the ICER for PEM compared with SoC was JPY6 299 749 per QALY. In a scenario without a restriction on the duration of PEM administration, the ICER was estimated at JPY21 408 155 per QALY.

Conclusions

Although outcomes varied depending on the PEM treatment duration and the medical cost setting after disease progression in the SoC group, PEM was suggested to be more cost-effective than SoC at the reference willingness-to-pay threshold of JPY15 million per QALY in Japan.
本研究旨在评估派姆单抗(PEM)治疗日本晚期结直肠癌高微卫星不稳定性或错配修复缺陷患者的成本效益。方法建立分割生存分析模型,预测PEM组和标准护理组的成本和质量调整生命年(QALYs)。模型外推的生存数据来自KEYNOTE-177试验。药品费用是根据日本官方定价计算的,其他医疗费用是根据一家健康保险协会提供的索赔数据库估算的。贴现率为2%。效用值来源于先前发表的研究。计算了PEM与SoC相比的增量成本效益比(ICER),并根据日本的支付意愿阈值进行了评估。进行敏感性分析以评估参数的不确定性。结果与SoC相比,PEM的增量成本估计为15 554 008日元,增量增益为2.47 qaly。基于这些结果,PEM与SoC的ICER每QALY为JPY6 299 749。在不限制PEM管理持续时间的情况下,ICER估计为每个QALY 21 408 155日元。结论尽管在SoC组中,PEM治疗时间和疾病进展后的医疗费用设置会导致结果不同,但在日本每个QALY的参考支付意愿阈值为1500万日元时,PEM被认为比SoC更具成本效益。
{"title":"Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Colorectal Cancer With High Microsatellite Instability or Mismatched Repair Deficiency in Japan","authors":"Seiya Taniguchi BS ,&nbsp;Kensuke Moriwaki MS, PhD ,&nbsp;Kosuke Morimoto MS ,&nbsp;Kojiro Shimozuma MD, PhD","doi":"10.1016/j.vhri.2025.101555","DOIUrl":"10.1016/j.vhri.2025.101555","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to evaluate the cost-effectiveness of pembrolizumab (PEM) for treating patients with advanced colorectal cancer with high microsatellite instability or mismatched repair deficiency in Japan.</div></div><div><h3>Methods</h3><div>A partitioned survival analysis model was developed to predict costs and quality-adjusted life-years (QALYs) in PEM and standard-of-care (SoC) groups. Survival data for model extrapolation were obtained from the KEYNOTE-177 trial. Drug costs were based on official Japanese pricing, and other medical costs were estimated using a claims database provided by a health insurance association. A 2% discount rate was applied. Utility values were derived from previously published studies. The incremental cost-effectiveness ratio (ICER) of PEM compared with SoC was calculated and evaluated against Japan’s willingness-to-pay threshold. Sensitivity analyses were conducted to assess parameter uncertainty.</div></div><div><h3>Results</h3><div>The incremental cost of PEM compared with SoC was estimated at JPY15 554 008 with an incremental gain of 2.47 QALYs. Based on these results, the ICER for PEM compared with SoC was JPY6 299 749 per QALY. In a scenario without a restriction on the duration of PEM administration, the ICER was estimated at JPY21 408 155 per QALY.</div></div><div><h3>Conclusions</h3><div>Although outcomes varied depending on the PEM treatment duration and the medical cost setting after disease progression in the SoC group, PEM was suggested to be more cost-effective than SoC at the reference willingness-to-pay threshold of JPY15 million per QALY in Japan.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"54 ","pages":"Article 101555"},"PeriodicalIF":1.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Randomized Online Grocery Store Trial to Test a Salient Tiered Food and Beverage Tax in Saudi Arabia 一项随机在线杂货店试验,以测试沙特阿拉伯显著的分层食品和饮料税。
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-12-09 DOI: 10.1016/j.vhri.2025.101516
Soye Shin PhD , Ada Mohammad Alqunaibet PhD , Reem Alsukait PhD , Amaal Alruwaily MPH , Volkan Cetinkaya PhD , Christopher H. Herbst PhD , Eric A. Finkelstein PhD

Objectives

Taxes on sugar-sweetened beverages in Saudi Arabia (SA) and other countries have reduced purchases of these beverages and their associated calories and sugar. However, expanding such taxes to cover a broader range of foods and nutrients may be more effective at improving overall diet quality.

Methods

We tested the effectiveness of a comprehensive, salient, tiered, nutrient-based food and beverage (F&B) tax using a fully functional online grocery store. A total of 644 SA shoppers were randomized into 1 of 3 conditions: no-tax (control); the current beverage tax (current tax); or the comprehensive, salient tiered F&B tax (comprehensive tax) targeting all products.

Results

The nutritional quality of the shopping baskets, measured by average Nutri-Score points (ie, base scores used to determine the Nutri-Score grades from A [healthiest] to E [least healthy]), weighted by serving size, did not differ statistically between the control and current beverage tax arms. However, the comprehensive tax led to healthier baskets, improving Nutri-Score points by 0.88 (95% CI −0.07 to 1.83) relative to the control arm and 1.16 points (95% CI 0.21 to 2.11) relative to the current tax arm, which is equivalent to a 3.04% and 4.05% increase, respectively.

Conclusions

These findings suggest that a comprehensive, salient tiered F&B tax has the potential to improve diet quality among SA shoppers.
目标:沙特阿拉伯(SA)和其他国家对含糖饮料征税,减少了这些饮料及其相关卡路里和糖的购买量。然而,将此类税收扩大到更广泛的食物和营养素范围,可能更有效地改善整体饮食质量。方法:我们使用功能齐全的在线杂货店测试了全面,突出,分层,营养为基础的食品和饮料(F&B)税的有效性。共有644名SA购物者被随机分为三种情况:无税(对照组);现行饮料税(当期税);或针对所有产品的全面、突出的分层餐饮税(综合税)。结果:购物篮的营养质量,以营养评分平均值(即用于确定营养评分从A[最健康]到E[最不健康]等级的基本分数)衡量,按份量加权,在对照组和现行饮料税组之间没有统计学差异。然而,综合税收带来了更健康的篮子,相对于对照组提高了0.88点(95% CI -0.07至1.83),相对于当前税收组提高了1.16点(95% CI 0.21至2.11),分别相当于提高了3.04%和4.05%。结论:这些发现表明,一个全面的、显著的分层餐饮税有可能改善SA购物者的饮食质量。
{"title":"A Randomized Online Grocery Store Trial to Test a Salient Tiered Food and Beverage Tax in Saudi Arabia","authors":"Soye Shin PhD ,&nbsp;Ada Mohammad Alqunaibet PhD ,&nbsp;Reem Alsukait PhD ,&nbsp;Amaal Alruwaily MPH ,&nbsp;Volkan Cetinkaya PhD ,&nbsp;Christopher H. Herbst PhD ,&nbsp;Eric A. Finkelstein PhD","doi":"10.1016/j.vhri.2025.101516","DOIUrl":"10.1016/j.vhri.2025.101516","url":null,"abstract":"<div><h3>Objectives</h3><div>Taxes on sugar-sweetened beverages in Saudi Arabia (SA) and other countries have reduced purchases of these beverages and their associated calories and sugar. However, expanding such taxes to cover a broader range of foods and nutrients may be more effective at improving overall diet quality.</div></div><div><h3>Methods</h3><div>We tested the effectiveness of a comprehensive, salient, tiered, nutrient-based food and beverage (F&amp;B) tax using a fully functional online grocery store. A total of 644 SA shoppers were randomized into 1 of 3 conditions: no-tax (control); the current beverage tax (current tax); or the comprehensive, salient tiered F&amp;B tax (comprehensive tax) targeting all products.</div></div><div><h3>Results</h3><div>The nutritional quality of the shopping baskets, measured by average Nutri-Score points (ie, base scores used to determine the Nutri-Score grades from A [healthiest] to E [least healthy]), weighted by serving size, did not differ statistically between the control and current beverage tax arms. However, the comprehensive tax led to healthier baskets, improving Nutri-Score points by 0.88 (95% CI −0.07 to 1.83) relative to the control arm and 1.16 points (95% CI 0.21 to 2.11) relative to the current tax arm, which is equivalent to a 3.04% and 4.05% increase, respectively.</div></div><div><h3>Conclusions</h3><div>These findings suggest that a comprehensive, salient tiered F&amp;B tax has the potential to improve diet quality among SA shoppers.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"52 ","pages":"Article 101516"},"PeriodicalIF":1.5,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145726129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measurement Properties of English and Chinese Versions of HeartQoL in a Multiethnic Asian Cohort With Cardiovascular Disease 亚洲多民族心血管疾病患者心脏生活质量中英文对照的测量特性
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-12-09 DOI: 10.1016/j.vhri.2025.101554
Rehena Sultana MSc , Felicia Jia Ler Ang PhD , Shir Lynn Lim MMed (Int Med) , Ru-San Tan MBBS , Nan Luo PhD , Yin Bun Cheung PhD , Mihir Gandhi PhD

Objectives

To evaluate the measurement properties of the HeartQoL questionnaire in assessing health-related quality of life (HRQoL) among multiethnic Asian patients with cardiovascular diseases (CVDs).

Methods

A cross-sectional survey was conducted among 556 CVD patients from 2 tertiary hospitals in Singapore. Patients self-assessed HRQoL using HeartQoL (a heart-disease-specific measure) and EuroQol 5-Dimension 5-Level (EQ-5D-5L) (a generic measure). HeartQoL includes a global scale and 2 subscales (physical and emotional), with higher values indicating better HRQoL. Measurement properties of HeartQoL were evaluated through convergent validity (Spearman’s ρ), internal consistency (Cronbach’s α), discriminative validity, and language equivalence between English and Chinese (Mandarin) versions.

Results

The mean age of recruited patients was 57.7 years (SD 11.5). 72.2% were male, and 461 (82.9%) responded to the survey in English. Cronbach’s α for the HeartQoL emotional, physical, and global scales were 0.86, 0.88, and 0.89, respectively. All scales were significantly positively correlated with relevant EQ-5D-5L items (r ≥ 0.4, P < .01) and negatively associated with CVD functional classification (P for trend < .01). Among Chinese ethnic patients, the 90% confidence interval for mean differences in HeartQoL scales between English and Mandarin versions was within ±0.5 SD, confirming measurement equivalence between the 2 language versions.

Conclusions

The HeartQoL demonstrated robust measurement properties in Asian CVD patients. The finding supports its use in clinical practice and research to assess and compare HRQoL among patients with CVDs.
目的:评价心脏质量问卷(HeartQoL)在评估亚洲多民族心血管疾病(cvd)患者健康相关生活质量(HRQoL)中的测量特性。方法:对新加坡2所三级医院556例心血管疾病患者进行横断面调查。患者使用HeartQoL(一种心脏病特异性测量)和EuroQol 5-Dimension 5-Level (EQ-5D-5L)(一种通用测量)自我评估HRQoL。HeartQoL包括整体量表和2个子量表(身体和情感),数值越高表明HRQoL越好。通过收敛效度(Spearman’s ρ)、内部一致性(Cronbach’s α)、判别效度和中英文(普通话)版本的语言等效性来评估HeartQoL的测量特性。结果:入选患者的平均年龄为57.7岁(SD 11.5)。72.2%为男性,461人(82.9%)用英语回答。HeartQoL情绪、身体和整体量表的Cronbach's α分别为0.86、0.88和0.89。各量表与相关EQ-5D-5L项呈显著正相关(r≥0.4,P < 0.01),与CVD功能分级呈显著负相关(P < 0.01)。在华裔患者中,英文和中文版本的HeartQoL量表平均差异的90%置信区间在±0.5 SD内,证实了两种语言版本之间的测量等效性。结论:HeartQoL在亚洲CVD患者中显示出可靠的测量特性。该发现支持其在临床实践和研究中用于评估和比较心血管疾病患者的HRQoL。
{"title":"Measurement Properties of English and Chinese Versions of HeartQoL in a Multiethnic Asian Cohort With Cardiovascular Disease","authors":"Rehena Sultana MSc ,&nbsp;Felicia Jia Ler Ang PhD ,&nbsp;Shir Lynn Lim MMed (Int Med) ,&nbsp;Ru-San Tan MBBS ,&nbsp;Nan Luo PhD ,&nbsp;Yin Bun Cheung PhD ,&nbsp;Mihir Gandhi PhD","doi":"10.1016/j.vhri.2025.101554","DOIUrl":"10.1016/j.vhri.2025.101554","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the measurement properties of the HeartQoL questionnaire in assessing health-related quality of life (HRQoL) among multiethnic Asian patients with cardiovascular diseases (CVDs).</div></div><div><h3>Methods</h3><div>A cross-sectional survey was conducted among 556 CVD patients from 2 tertiary hospitals in Singapore. Patients self-assessed HRQoL using HeartQoL (a heart-disease-specific measure) and EuroQol 5-Dimension 5-Level (EQ-5D-5L) (a generic measure). HeartQoL includes a global scale and 2 subscales (physical and emotional), with higher values indicating better HRQoL. Measurement properties of HeartQoL were evaluated through convergent validity (Spearman’s ρ), internal consistency (Cronbach’s α), discriminative validity, and language equivalence between English and Chinese (Mandarin) versions.</div></div><div><h3>Results</h3><div>The mean age of recruited patients was 57.7 years (SD 11.5). 72.2% were male, and 461 (82.9%) responded to the survey in English. Cronbach’s α for the HeartQoL emotional, physical, and global scales were 0.86, 0.88, and 0.89, respectively. All scales were significantly positively correlated with relevant EQ-5D-5L items (r ≥ 0.4, <em>P</em> &lt; .01) and negatively associated with CVD functional classification (<em>P</em> for trend &lt; .01). Among Chinese ethnic patients, the 90% confidence interval for mean differences in HeartQoL scales between English and Mandarin versions was within ±0.5 SD, confirming measurement equivalence between the 2 language versions.</div></div><div><h3>Conclusions</h3><div>The HeartQoL demonstrated robust measurement properties in Asian CVD patients. The finding supports its use in clinical practice and research to assess and compare HRQoL among patients with CVDs.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"54 ","pages":"Article 101554"},"PeriodicalIF":1.5,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145716047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measurement Properties and Cross-Cultural Invariance of the French Decisional Conflict Scale in Chronic Pain: Secondary Analysis of the DECIDE-PAIN Survey 法国慢性疼痛决策冲突量表的测量特性和跨文化不变性:decision - Pain调查的二次分析
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-29 DOI: 10.1016/j.vhri.2025.101551
Florian Naye PhD , Maxime Sasseville PhD , Karine Toupin-April PhD , France Légaré PhD , Chloé Cachinho MSc , Thomas Gérard MSc , Valentin Vaillant MSc , Alison M. Hoens MSc , Yannick Tousignant-Laflamme PhD , Simon Décary PhD

Objectives

Evidence on the validity of the French version of the Decisional Conflict Scale (DCS) remains limited, especially among people living with chronic noncancer pain in Canada. This study examined the measurement properties of the French 16-item DCS and assessed its cross-cultural measurement invariance in this population.

Methods

We conducted a secondary analysis of a pan-Canadian cross-sectional online survey following the Consensus-Based Standards for the Selection of Health Measurement Instruments guidance. We evaluated score distribution, including ceiling and floor effects. We assessed readability, internal consistency, structural validity of a hypothesized 5-factor model, and convergent and discriminant validities. We tested measurement invariance between the French and English versions.

Results

We analyzed data from 270 French-speaking Canadians (mean age = 51; 60% male; 54.8% with less than a university diploma; and 70.4% with limited health literacy). The French DCS showed good readability (Flesch-Kincaid Grade Level: 5.6), no ceiling or floor effects for the total score, and high internal consistency (ω = 0.95). The 5-factor structure was supported (CFI = 0.98). Convergent validity was confirmed (AVE: 0.61-0.72), but discriminant validity was poor (AVE < squared interfactor correlations). Measurement invariance was supported at configural, metric, scalar, and strict levels when compared with 985 English-speaking respondents (mean age = 51; 47.5% male; 50% with less than a university diploma; and 71.3% with limited health literacy).

Conclusions

The French 16-item DCS has acceptable measurement properties and cross-cultural measurement invariance in people living with chronic noncancer pain. Further research is necessary to enhance its validity, possibly by reexamining its factor structure.
关于法语版决策冲突量表(DCS)有效性的证据仍然有限,特别是在加拿大患有慢性非癌性疼痛的人群中。本研究考察了法语16项DCS的测量特性,并评估了其在该人群中的跨文化测量不变性。方法:我们根据基于共识的健康测量工具选择标准指南,对一项泛加拿大横断面在线调查进行了二次分析。我们评估了分数分布,包括上限和下限效应。我们评估了一个假设的五因素模型的可读性、内部一致性、结构效度以及收敛效度和判别效度。我们测试了法语和英语版本之间的测量不变性。结果:我们分析了270名讲法语的加拿大人的数据(平均年龄为51岁,60%为男性,54.8%的人没有大学文凭,70.4%的人健康知识有限)。法语DCS具有良好的可读性(Flesch-Kincaid Grade Level: 5.6),总分没有上限或下限效应,内部一致性高(ω = 0.95)。5因子结构得到支持(CFI = 0.98)。收敛效度得到证实(AVE: 0.61-0.72),但区分效度较差(AVE <;因子间相关的平方)。与985名说英语的受访者(平均年龄为51岁,47.5%为男性,50%低于大学文凭,71.3%健康知识有限)相比,测量不变性在构形、公制、标量和严格水平上得到了支持。结论法国16项DCS在慢性非癌性疼痛患者中具有可接受的测量特性和跨文化测量不变性。有必要进一步研究以提高其有效性,可能需要重新审视其因素结构。
{"title":"Measurement Properties and Cross-Cultural Invariance of the French Decisional Conflict Scale in Chronic Pain: Secondary Analysis of the DECIDE-PAIN Survey","authors":"Florian Naye PhD ,&nbsp;Maxime Sasseville PhD ,&nbsp;Karine Toupin-April PhD ,&nbsp;France Légaré PhD ,&nbsp;Chloé Cachinho MSc ,&nbsp;Thomas Gérard MSc ,&nbsp;Valentin Vaillant MSc ,&nbsp;Alison M. Hoens MSc ,&nbsp;Yannick Tousignant-Laflamme PhD ,&nbsp;Simon Décary PhD","doi":"10.1016/j.vhri.2025.101551","DOIUrl":"10.1016/j.vhri.2025.101551","url":null,"abstract":"<div><h3>Objectives</h3><div>Evidence on the validity of the French version of the Decisional Conflict Scale (DCS) remains limited, especially among people living with chronic noncancer pain in Canada. This study examined the measurement properties of the French 16-item DCS and assessed its cross-cultural measurement invariance in this population.</div></div><div><h3>Methods</h3><div>We conducted a secondary analysis of a pan-Canadian cross-sectional online survey following the Consensus-Based Standards for the Selection of Health Measurement Instruments guidance. We evaluated score distribution, including ceiling and floor effects. We assessed readability, internal consistency, structural validity of a hypothesized 5-factor model, and convergent and discriminant validities. We tested measurement invariance between the French and English versions.</div></div><div><h3>Results</h3><div>We analyzed data from 270 French-speaking Canadians (mean age = 51; 60% male; 54.8% with less than a university diploma; and 70.4% with limited health literacy). The French DCS showed good readability (Flesch-Kincaid Grade Level: 5.6), no ceiling or floor effects for the total score, and high internal consistency (ω = 0.95). The 5-factor structure was supported (CFI = 0.98). Convergent validity was confirmed (AVE: 0.61-0.72), but discriminant validity was poor (AVE &lt; squared interfactor correlations). Measurement invariance was supported at configural, metric, scalar, and strict levels when compared with 985 English-speaking respondents (mean age = 51; 47.5% male; 50% with less than a university diploma; and 71.3% with limited health literacy).</div></div><div><h3>Conclusions</h3><div>The French 16-item DCS has acceptable measurement properties and cross-cultural measurement invariance in people living with chronic noncancer pain. Further research is necessary to enhance its validity, possibly by reexamining its factor structure.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"54 ","pages":"Article 101551"},"PeriodicalIF":1.5,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145617555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review 血管内皮生长因子抑制剂治疗湿性年龄相关性黄斑变性的成本-效果:一项系统综述
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-25 DOI: 10.1016/j.vhri.2025.101542
Ganesh S. Paneerselvam PhD , Ng J. Wai Bpharm , Lim J. Sheng Bpharm , Lee K.C. Kenneth PhD

Objectives

To evaluate the cost-effectiveness of VEGF inhibitors, ranibizumab, aflibercept, bevacizumab, brolucizumab, pegaptanib, and conbercept for wAMD treatment.

Methods

A systematic search was conducted in PubMed, Cochrane, and SpringerLink databases to identify cost-effectiveness analyses and cost-utility analyses related to wAMD treatment. Eligible studies were assessed using Drummond’s 10-point checklist to evaluate methodological quality. The extracted data included intervention costs, quality-adjusted life-years, and incremental cost-effectiveness ratios.

Results

Twenty-two studies met the inclusion criteria. Bevacizumab and brolucizumab were frequently reported as cost-effective alternatives, offering comparable or superior visual outcomes at lower costs than ranibizumab or aflibercept. Pegaptanib was consistently less cost-effective. Findings for ranibizumab versus aflibercept varied by treatment regimen and analytic assumptions. Across studies, cost-effectiveness estimates were influenced by model perspective, time horizon, exclusion of adverse events, and single-eye modeling. A further limitation is that in contexts of non-inferior efficacy, small incremental quality-adjusted life-years differences may artificially inflate incremental cost-effectiveness ratios, potentially overstating the costs relative to benefits.

Conclusions

Decision making in wAMD treatment requires more thorough economic evaluations that incorporate standardized methodologies and lengthy cost assessments.
目的评价VEGF抑制剂、雷尼单抗、阿非利塞普、贝伐单抗、brolucizumab、pegaptanib和conbercept在wAMD治疗中的成本-效果。方法系统检索PubMed、Cochrane和SpringerLink数据库,确定与wAMD治疗相关的成本-效果分析和成本-效用分析。使用Drummond的10点检查表评估合格的研究,以评估方法学质量。提取的数据包括干预成本、质量调整寿命年和增量成本-效果比。结果22项研究符合纳入标准。贝伐单抗和布卢珠单抗经常被报道为具有成本效益的替代品,以更低的成本提供与雷尼单抗或阿非利塞相当或更好的视力结果。Pegaptanib的成本效益一直较低。雷尼单抗与阿非利赛的结果因治疗方案和分析假设而异。在所有研究中,成本-效果估计受到模型视角、时间范围、排除不良事件和单眼建模的影响。进一步的限制是,在非劣效的情况下,小的增量质量调整寿命年差异可能人为地夸大增量成本-效果比,潜在地夸大了相对于收益的成本。结论:wAMD治疗的决策需要更彻底的经济评估,包括标准化的方法和冗长的成本评估。
{"title":"Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review","authors":"Ganesh S. Paneerselvam PhD ,&nbsp;Ng J. Wai Bpharm ,&nbsp;Lim J. Sheng Bpharm ,&nbsp;Lee K.C. Kenneth PhD","doi":"10.1016/j.vhri.2025.101542","DOIUrl":"10.1016/j.vhri.2025.101542","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the cost-effectiveness of VEGF inhibitors, ranibizumab, aflibercept, bevacizumab, brolucizumab, pegaptanib, and conbercept for wAMD treatment.</div></div><div><h3>Methods</h3><div>A systematic search was conducted in PubMed, Cochrane, and SpringerLink databases to identify cost-effectiveness analyses and cost-utility analyses related to wAMD treatment. Eligible studies were assessed using Drummond’s 10-point checklist to evaluate methodological quality. The extracted data included intervention costs, quality-adjusted life-years, and incremental cost-effectiveness ratios.</div></div><div><h3>Results</h3><div>Twenty-two studies met the inclusion criteria. Bevacizumab and brolucizumab were frequently reported as cost-effective alternatives, offering comparable or superior visual outcomes at lower costs than ranibizumab or aflibercept. Pegaptanib was consistently less cost-effective. Findings for ranibizumab versus aflibercept varied by treatment regimen and analytic assumptions. Across studies, cost-effectiveness estimates were influenced by model perspective, time horizon, exclusion of adverse events, and single-eye modeling. A further limitation is that in contexts of non-inferior efficacy, small incremental quality-adjusted life-years differences may artificially inflate incremental cost-effectiveness ratios, potentially overstating the costs relative to benefits.</div></div><div><h3>Conclusions</h3><div>Decision making in wAMD treatment requires more thorough economic evaluations that incorporate standardized methodologies and lengthy cost assessments.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"53 ","pages":"Article 101542"},"PeriodicalIF":1.5,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of Resmetirom for Metabolic Dysfunction-Associated Steatohepatitis in Brazil 雷舒美治疗巴西代谢功能障碍相关脂肪性肝炎的成本-效果
IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-20 DOI: 10.1016/j.vhri.2025.101526
Windson Hebert Araújo Soares BPharm , Guilherme Grossi Lopes Cançado MD, MSc, PhD , André Soares Motta-Santos PhD

Objectives

To assess the cost-effectiveness of resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis in Brazil.

Methods

A Markov model was developed using TreeAge Pro® 2009 from the perspective of the Brazilian public healthcare system. The model used a 20-year time horizon with annual cycles. Seven health states were included: absence of fibrosis (F0), mild to advanced fibrosis (F1, F2, and F3), cirrhosis (F4), liver transplantation, and mortality. Costs were reported in Brazilian reais (BRL) and purchasing power parity US dollars (PPP-USD), and outcomes were measured in quality-adjusted life-years (QALYs). Both deterministic and probabilistic sensitivity analyses were performed. Incremental cost-effectiveness ratios (ICERs) were compared with multiple willingness-to-pay thresholds to determine cost-effectiveness.

Results

Resmetirom demonstrated an average incremental cost of 121 762 PPP-USD and an incremental gain of 1.05 QALYs compared with placebo. The mean ICER was approximately 40 017 PPP-USD/QALY, with a symmetric distribution and moderate variability (30 869-50 234 PPP-USD/QALY). The ICER scatterplot showed a predominance in the northeast quadrant, with no instances of dominance. The model was consistent across variations in input parameters.

Conclusions

Resmetirom was more effective than placebo but incurred higher costs. From the healthcare system perspective, it was not considered cost-effective under Brazil’s conventional willingness-to-pay thresholds (1 to 3 times gross domestic product per capita per QALY) or thresholds based on opportunity cost. These findings underscore the need for caution in coverage and reimbursement decisions.
目的评估雷司替罗治疗巴西代谢功能障碍相关脂肪性肝炎的成本-效果。方法采用TreeAge Pro®2009软件从巴西公共卫生系统的角度建立马尔可夫模型。该模型使用了20年的时间范围,并以年为周期。包括7种健康状态:无纤维化(F0)、轻度至晚期纤维化(F1、F2和F3)、肝硬化(F4)、肝移植和死亡率。成本以巴西雷亚尔(BRL)和购买力平价美元(PPP-USD)报告,结果以质量调整生命年(QALYs)衡量。进行了确定性和概率敏感性分析。将增量成本-效果比(ICERs)与多个支付意愿阈值进行比较,以确定成本-效果。结果与安慰剂相比,resmetirom的平均增量成本为121 762 PPP-USD,增量收益为1.05 qaly。平均ICER约为40 017 PPP-USD/QALY,具有对称分布和中等变异性(30 869-50 234 PPP-USD/QALY)。ICER散点图显示东北象限为优势,无优势实例。该模型在输入参数的变化中是一致的。结论瑞司替龙的治疗效果优于安慰剂,但成本较高。从医疗保健系统的角度来看,在巴西传统的支付意愿阈值(每QALY人均国内生产总值的1至3倍)或基于机会成本的阈值下,它被认为不具有成本效益。这些发现强调了在覆盖范围和报销决定方面需要谨慎。
{"title":"Cost-Effectiveness of Resmetirom for Metabolic Dysfunction-Associated Steatohepatitis in Brazil","authors":"Windson Hebert Araújo Soares BPharm ,&nbsp;Guilherme Grossi Lopes Cançado MD, MSc, PhD ,&nbsp;André Soares Motta-Santos PhD","doi":"10.1016/j.vhri.2025.101526","DOIUrl":"10.1016/j.vhri.2025.101526","url":null,"abstract":"<div><h3>Objectives</h3><div>To assess the cost-effectiveness of resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis in Brazil.</div></div><div><h3>Methods</h3><div>A Markov model was developed using TreeAge Pro® 2009 from the perspective of the Brazilian public healthcare system. The model used a 20-year time horizon with annual cycles. Seven health states were included: absence of fibrosis (F0), mild to advanced fibrosis (F1, F2, and F3), cirrhosis (F4), liver transplantation, and mortality. Costs were reported in Brazilian reais (BRL) and purchasing power parity US dollars (PPP-USD), and outcomes were measured in quality-adjusted life-years (QALYs). Both deterministic and probabilistic sensitivity analyses were performed. Incremental cost-effectiveness ratios (ICERs) were compared with multiple willingness-to-pay thresholds to determine cost-effectiveness.</div></div><div><h3>Results</h3><div>Resmetirom demonstrated an average incremental cost of 121 762 PPP-USD and an incremental gain of 1.05 QALYs compared with placebo. The mean ICER was approximately 40 017 PPP-USD/QALY, with a symmetric distribution and moderate variability (30 869-50 234 PPP-USD/QALY). The ICER scatterplot showed a predominance in the northeast quadrant, with no instances of dominance. The model was consistent across variations in input parameters.</div></div><div><h3>Conclusions</h3><div>Resmetirom was more effective than placebo but incurred higher costs. From the healthcare system perspective, it was not considered cost-effective under Brazil’s conventional willingness-to-pay thresholds (1 to 3 times gross domestic product per capita per QALY) or thresholds based on opportunity cost. These findings underscore the need for caution in coverage and reimbursement decisions.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"53 ","pages":"Article 101526"},"PeriodicalIF":1.5,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Value in health regional issues
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1